Massive study looks at benefits, risks of GLP-1 weight-loss drugs
As demand for weight-loss injections sold under brand names such as Ozempic and Wegovy continues to soar, a study has uncovered neurological and behavioral health benefits amid risks for pancreatitis and kidney disease.
Popular GLP-1 medications may have health benefits that extend beyond weight loss and blood sugar control, a new study finds
Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to reduce the risks of substance abuse disorders, psychosis, infections, some kinds of cancer and dementia,
Popular GLP-1 Drugs Are Shaping Health Beyond Weight Loss & Diabetes
In all, researchers found that people taking GLP-1 medications had lower risks for 42 health outcomes, including liver failure, lung failure, cardiac arrest, aspiration pneumonia and shock.
GLP-1 weight-loss drugs may cut risk of dementia and other conditions
GLP-1 weight loss drugs - such as Wegovy and Mounjaro - may reduce risk of conditions including Alzheimer’s disease and dementia.
Not Just For Weight Loss: GLP-1 Drugs May Affect Addiction And Dementia Risk
Over 2 million people were included in new research to test these drugs against 175 different health outcomes.
GLP-1 receptor agonists tied to risks and benefits beyond weight loss
Reduced risks seen for neurocognitive, coagulation, cardiometabolic disorders; increased risks seen for GI, arthritic disorders
Major Study Exposes New Health Risks of Weight Loss Drugs
A new study uncovers how widely used weight loss drugs like Ozempic impact various health conditions while posing notable risks.
GLP-1 weight loss drugs could help people with impulse control and addiction disorders, say researchers
Glucagon-like peptide-1 receptor agonists (GLP-1RAs), used to treat diabetes and for weight loss, may be linked with a reduced risk of substance use and neurocognitive disorders, a US study in people with type 2 diabetes found,
Weight-Loss Drugs Like Ozempic Linked To Lower Risk Of 42 Conditions
Some outcomes, like reduced risk of cardiovascular disease and increased chance of nausea, were expected. But others took researchers by surprise.
Sweeping review suggests weight-loss drugs’ effect on 175 conditions
The findings, based on an analysis of records from 2.5 million VA patients, support much of what scientists already suspected but contain surprises, too.
GLP-1 Drugs Linked to Lower Alzheimer's Risk Amid Safety Warnings
A new study finds that people taking GLP-1 medications like Ozempic, Wegovy, and Mounjaro face up to a 12% lower risk of developing Alzheimer's disease. Researchers at Washington University in St. Louis examined 215,
Largest-ever Ozempic and GLP-1 drug study finds they lower risk of 42 health conditions, including heart attacks and Alzheimer’s disease
The study included nearly 2 million patients, making it the largest ever conducted on this group of glucagon-like peptide-1 ...
GLP-1 drugs linked to lower dementia risk, higher risk of kidney, stomach issues
A new study compares the benefits and risks of taking GLP-1 medications for weight loss, including risks of dementia, ...
LifeVantage: Bold Move Into The GLP-1 Weight Loss Market Turns Out To Be A Major Winner - Buy
LifeVantage's new MindBody GLP-1 System is riding the coattails of GLP-1 weight loss drugs. See why I rate LFVN stock as a ...
Eli Lilly Stock Tumbles on Slower-Than-Expected Weight Loss Drug Sales. Is This a Buying Opportunity?
Eli Lilly unexpectedly lowered its full-year 2024 guidance. The miss appears to stem from a lack of the typical December ...